Inhibikase Therapeutics, Inc. (IKT)

Market Cap	131.70M
Revenue (ttm)	1
Net Income (ttm)	-19.57M
Shares Out	67.19M
EPS (ttm)	-2.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,277
Open	1.960
Previous Close	1.970
Day's Range	1.960 - 2.020
52-Week Range	0.798 - 3.820
Beta	1.12
Analysts	Strong Buy
Price Target	6.50 (+231.62%)
Earnings Date	Nov 14, 2024

About IKT

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collab...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 23, 2020
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: IKT
• Website: https://www.inhibikase.com

Financial Performance

In 2023, Inhibikase Therapeutics's revenue was $260,501, an increase of 111.03% compared to the previous year's $123,440. Losses were -$19.03 million, 5.40% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for IKT stock is "Strong Buy." The 12-month stock price forecast is $6.5, which is an increase of 231.62% from the latest price.

Price Target

$6.5

(231.62% upside)

Analyst Consensus: Strong Buy